Breanne D W Karanikolas1, Marxa L Figueiredo, Lily Wu. 1. Department of Molecular and Medical Pharmacology, Institute of Molecular Medicine, University of California Los Angeles, Los Angeles, California 90095-1738, USA.
Abstract
BACKGROUND: Although most prostate cancers respond well to initial treatments, a fraction of prostate cancers are more aggressive and will recur and metastasize. At that point, there are few treatment options available. Significant efforts have been made to identify biomarkers that will identify these more aggressive cancers to tailor a more vigorous treatment in order to improve outcome. Polycomb Group protein enhancer of zeste 2 (EZH2) was found to be overexpressed in metastatic prostate tumors, and is considered an excellent candidate for such a biomarker. Scattered studies have found that EZH2 overexpression causes neoplastic transformation, invasion, and growth of prostate cells. However, these studies utilized different systems and cell lines, and so are difficult to correlate with one another. METHODS: In this study, a comprehensive evaluation of the phenotypic effects of EZH2 in a panel of five prostate cancer cell lines was performed. By using multiple cell lines, and examining overexpression and knockdown of EZH2 concurrently, a broad view of EZH2's role in prostate cancer was achieved. RESULTS: Overexpression of EZH2 led to more aggressive behaviors in all prostate cell lines tested. In contrast, downregulation of EZH2 reduced invasion and tumorigenicity of androgen-independent (AI) cell lines CWR22Rv1, PC3, and DU145, but not of androgen-dependent (AD) cell lines LAPC4 and LNCaP. CONCLUSIONS: Findings from this study suggest that AI prostate tumors are more dependent on EZH2 expression than AD tumors. Our observations provide an explanation for the strong correlation between EZH2 overexpression and advanced stage, aggressive prostate cancers.
BACKGROUND: Although most prostate cancers respond well to initial treatments, a fraction of prostate cancers are more aggressive and will recur and metastasize. At that point, there are few treatment options available. Significant efforts have been made to identify biomarkers that will identify these more aggressive cancers to tailor a more vigorous treatment in order to improve outcome. Polycomb Group protein enhancer of zeste 2 (EZH2) was found to be overexpressed in metastatic prostate tumors, and is considered an excellent candidate for such a biomarker. Scattered studies have found that EZH2 overexpression causes neoplastic transformation, invasion, and growth of prostate cells. However, these studies utilized different systems and cell lines, and so are difficult to correlate with one another. METHODS: In this study, a comprehensive evaluation of the phenotypic effects of EZH2 in a panel of five prostate cancer cell lines was performed. By using multiple cell lines, and examining overexpression and knockdown of EZH2 concurrently, a broad view of EZH2's role in prostate cancer was achieved. RESULTS: Overexpression of EZH2 led to more aggressive behaviors in all prostate cell lines tested. In contrast, downregulation of EZH2 reduced invasion and tumorigenicity of androgen-independent (AI) cell lines CWR22Rv1, PC3, and DU145, but not of androgen-dependent (AD) cell lines LAPC4 and LNCaP. CONCLUSIONS: Findings from this study suggest that AI prostate tumors are more dependent on EZH2 expression than AD tumors. Our observations provide an explanation for the strong correlation between EZH2 overexpression and advanced stage, aggressive prostate cancers.
Authors: A G Sorensen; S Patel; C Harmath; S Bridges; J Synnott; A Sievers; Y H Yoon; E J Lee; M C Yang; R F Lewis; G J Harris; M Lev; P W Schaefer; B R Buchbinder; G Barest; K Yamada; J Ponzo; H Y Kwon; J Gemmete; J Farkas; A L Tievsky; R B Ziegler; M R Salhus; R Weisskoff Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang Journal: Science Date: 2002-09-26 Impact factor: 47.728
Authors: Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan Journal: Nature Date: 2002-10-10 Impact factor: 49.962
Authors: Daniel R Rhodes; Martin G Sanda; Arie P Otte; Arul M Chinnaiyan; Mark A Rubin Journal: J Natl Cancer Inst Date: 2003-05-07 Impact factor: 13.506
Authors: Avinash Khanna; Alexandre Côté; Shilpi Arora; Ludivine Moine; Victor S Gehling; Jehrod Brenneman; Nico Cantone; Jacob I Stuckey; Shruti Apte; Ashwin Ramakrishnan; Kamil Bruderek; William D Bradley; James E Audia; Richard T Cummings; Robert J Sims; Patrick Trojer; Julian R Levell Journal: ACS Med Chem Lett Date: 2020-03-26 Impact factor: 4.345
Authors: Jeffrey M Bhasin; Byron H Lee; Lars Matkin; Margaret G Taylor; Bo Hu; Yaomin Xu; Cristina Magi-Galluzzi; Eric A Klein; Angela H Ting Journal: Cell Rep Date: 2015-11-25 Impact factor: 9.423
Authors: Cody J Peer; Mahadev Rao; Shawn D Spencer; Shandiz Shahbazi; Patricia S Steeg; David S Schrump; William D Figg Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2013-01-09 Impact factor: 3.205
Authors: Yuanshuo Alice Wang; John Sfakianos; Ashutosh K Tewari; Carlos Cordon-Cardo; Natasha Kyprianou Journal: Oncogene Date: 2020-10-12 Impact factor: 9.867